Key facts
- This page summarizes Michael G. Bator's Form 4 filing for Cytosorbents Corp (CTSO).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 04 Mar 2025, 21:00.
Michael G. Bator - 24 Feb 2025 Form 4 Insider Report for Cytosorbents Corp (CTSO)
- Reporting relationship
- Director
- Issuer ticker
- CTSO
- Reported as of
- 24 Feb 2025
- Net transaction value
- -$6,643
- SEC form
- 4
- Accepted by SEC
- 04 Mar 2025, 21:00:21 UTC
- Prior SEC filing
- 22 Jan 2025
- Next SEC filing
- 08 Aug 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Peter J. Mariani attorney-in-fact Michael G. Bator
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Michael G. Bator filed Form 4 for Cytosorbents Corp (CTSO) on 04 Mar 2025.
Change
- Previous filing in this sequence was filed on 22 Jan 2025.
- Current net transaction value: -$6,643.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CTSO
transaction
Common Stock
Exercise of out-of-the-money derivative security
- Transaction value
- $11,300
- Shares
- +10,000
- Change %
- +7.1%
- Price
- $1.13
- Shares after
- 151,273
- Date
- 24 Feb 2025
- Ownership
- Direct
- Footnotes
- F1, F2, F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CTSO
transaction
Derivative
Series A Right Warrants (right to buy)
Exercise of out-of-the-money derivative security
- Transaction value
- $17,943
- Shares
- -15,879
- Change %
- -100%
- Price
- $1.13
- Shares after
- 0
- Date
- 24 Feb 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 15,879
- Exercise price
- $1.13
- Footnotes
- F1, F2, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
On January 17, 2025, the Reporting Person exercised certain subscription rights certificates received pursuant to a rights offering (the "Rights Offering") with CytoSorbents Corporation (the "Issuer") whereby the Reporting Person received Units consisting of an aggregate of 15,879 (i) shares of Issuer's common stock, par value $0.001 per share (the "Common Stock"), (ii) Series A Warrants to purchase one share of Common Stock, and (iii) Series B Warrants to purchase one share of Common Stock, at a subscription purchase price of $1.00 per unit for an aggregate cost of $15,879. The Rights Offering closed on January 10, 2025 (the "Closing Date").
Footnote F2
The Series A Right Warrants exercise price was calculated as 90% of the 5-day volume weighted average price of the Issuer's Common Stock over the 5-trading days prior to the expiration date of the Series A Right Warrants, rounded down to the nearest whole cent but (x) not lower than $1.00 and (y) not higher than $2.00.
Footnote F3
Includes (a) the following restricted stock units ("RSUs") which will vest upon a "Change of Control" of the Company, as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (i) 3,300 RSUs granted on March 15, 2018, (ii) 6,000 RSUs granted on February 24, 2017, and (iii) 60,000 RSUs granted on June 7, 2016, and (b) 81,973 shares of Common Stock owned by the Reporting Person.
Footnote F4
The Reporting Person's remaining 5,879 Series A Warrants expired unexercised on February 24, 2025.
SEC remarks
Exhibit 24.1 Power of Attorney